Search research articles
Contact Us
Filters
Showing results (221-230 of 265) with videos related to
Page
of 27
Sort By:
The Oncologist
|
January 26, 2026
Clinical characteristics and Drug-Drug interactions in HER2+ breast cancer treated with T-DXd: Real-World data from the DE-REAL study
Simona Pisegna, Simone Scagnoli, Gabriella Gentile, et al.
International Journal of Molecular Sciences
|
July 29, 2025
HER2-Driven Breast Cancer: Role of the Chaperonin HSP90 in Modulating Response to Trastuzumab-Based Therapeutic Combinations
Italia Falcone, Elena Giontella, Stefano Giuliani, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
March 8, 2024
TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication
Sara Iachettini, Irene Terrenato, Manuela Porru, et al.
Minerva Endocrinology
|
December 11, 2024
Neuroendocrine neoplasms of the breast: a multicenter retrospective Italian study
Roberto Baldelli, Marta Franco, Valerio Renzelli, et al.
Journal of Personalized Medicine
|
August 25, 2023
An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant Chemotherapy
Antonio Franco, Alba Di Leone, Marco Conti, et al.
NPJ Breast Cancer
|
September 8, 2023
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, et al.
Frontiers in Oncology
|
July 13, 2023
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study
Agnese Fabbri, Fabrizio Nelli, Andrea Botticelli, et al.
Future Oncology (London, England)
|
June 14, 2025
Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study
Franco Antonio, Luisa Carbognin, Ida Paris, et al.
Cancers
|
October 14, 2022
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making
Francesco Pavese, Ettore Domenico Capoluongo, Margherita Muratore, et al.
Cancers
|
April 23, 2022
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review
Mattia Garutti, Gaia Griguolo, Andrea Botticelli, et al.
Page
of 27
Search research articles
Search
Showing results (221-230 of 265) with videos related to
Sort By:
Page
of 27
The Oncologist
|
January 26, 2026
Clinical characteristics and Drug-Drug interactions in HER2+ breast cancer treated with T-DXd: Real-World data from the DE-REAL study
Simona Pisegna, Simone Scagnoli, Gabriella Gentile, et al.
International Journal of Molecular Sciences
|
July 29, 2025
HER2-Driven Breast Cancer: Role of the Chaperonin HSP90 in Modulating Response to Trastuzumab-Based Therapeutic Combinations
Italia Falcone, Elena Giontella, Stefano Giuliani, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
March 8, 2024
TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication
Sara Iachettini, Irene Terrenato, Manuela Porru, et al.
Minerva Endocrinology
|
December 11, 2024
Neuroendocrine neoplasms of the breast: a multicenter retrospective Italian study
Roberto Baldelli, Marta Franco, Valerio Renzelli, et al.
Journal of Personalized Medicine
|
August 25, 2023
An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant Chemotherapy
Antonio Franco, Alba Di Leone, Marco Conti, et al.
NPJ Breast Cancer
|
September 8, 2023
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, et al.
Frontiers in Oncology
|
July 13, 2023
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study
Agnese Fabbri, Fabrizio Nelli, Andrea Botticelli, et al.
Future Oncology (London, England)
|
June 14, 2025
Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study
Franco Antonio, Luisa Carbognin, Ida Paris, et al.
Cancers
|
October 14, 2022
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making
Francesco Pavese, Ettore Domenico Capoluongo, Margherita Muratore, et al.
Cancers
|
April 23, 2022
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review
Mattia Garutti, Gaia Griguolo, Andrea Botticelli, et al.
Page
of 27